Nam Ha Pharmaceutical Joint Stock Company (Nam Ha Pharma) has recently been ranked in “Top 5 prestigious Vietnamese Oriental Medicine Companies”. This is the third time in a row Nam Ha Pharmaceutical has been honored with this title.

According to Vietnam Report, the ranking of “Top 5 Prestigious Vietnamese Oriental Medicine Companies” is built based on independent research and evaluation results according to international standards of 3 criteria: financial capacity, media reputation, trust from the stakeholders and the social community. The program is annually surveyed by Vietnam Report to recognize and honor the achievements of large enterprises with effective and sustainable production and business activities.

Nam Ha Pharma received “Top 5 Prestigious Vietnamese Oriental Medicine Companies” award

Nam Ha Pharma is one of the few pharmaceutical enterprises in Vietnam that has succeeded in transforming to adapt to the “new situation”, which includes shifting in production and business to solve problems and difficulties that still exist from the outbreak of the Covid-19 pandemic.

The “sweet fruit” from those efforts is a prosperous recovery, creating a steady growth momentum for Nam Ha Pharma. The estimated net revenue of the company in 2022 is more than 1,000 billion VND (approx. 42,3 million USD, surging 8.8% year-on-year 2021).

2022 is also a breakthrough year for traditional pharmaceutical products of Nam Ha Pharma, in which the most prominent one is the “Bổ Phê Nam Hà (Nam Ha Lung Tonic)” product line with an impressive consumption level. Even during the most complicated and difficult time of the pandemic, Nam Ha Pharma still ensured the supply for the increasing demand of the market. This is thanks to the strategic vision of the leadership for many consecutive years, which has actively developed and expanded the GACP-WHO standard medicinal plant growing area in Vietnam, as well as investing, researching, innovating and improving production processes, upgrading production and business systems to meet GMP-GLP-GSP WHO standards and quality management systems to meet ISO-9001: 2015 standards.

Bổ Phế Nam Hà product line – Proud to be a national brand

In addition to Bổ Phế Nam Hà, the oldest cough medicine in Vietnam, Nam Ha Pharma also manufactures a wide range of Western medicine products in order to complete the National Target Program, and contributes to the mission of protecting and taking care of Vietnamese people’s health.

After more than 62 years of development, Nam Ha Pharma has applied automation and digitization systems in managing and operating production and business. The company’s distribution system stretches across Vietnam, with more than 20,000 pharmacies and hundreds of experienced and reputable pharmacists.

In addition to business activities, Nam Ha Pharma also actively implements activities such as training courses, promotion programs, and online seminars to ensure social distancing but still be able to provide product information to each customer and pharmacist. Keeping connected with sales distribution channels, receiving and responding to feedback quickly is a plus point that helps Nam Ha Pharma products to be trusted and welcomed by customers and consumers.

Based on the strong potential from qualified raw materials, modern production and distribution conditions, and a high-quality human resource system, over the past 62 years, Nam Ha Pharma’s products have remained strong and constantly developed in the market.  The company was honored to be ranked in “Top 5 Prestigious Vietnamese Oriental Medicine Companies” in 3 years, and received many reputed awards by organizations.

With the right direction and solid business foundation, in 2022, Nam Ha Pharma has completed and exceeded the set targets, well complied with the obligation to pay the state budget, and ensured social security for nearly 1000 employees with average income increased every year and welfare regimes are always taken care of and guaranteed.

Nam Ha Pharma always always care and provide the best working opportunities for its employees

“Nam Ha Pharma’s achievements nowadays are thanks to the contribution and dedication of the company’s employees, especially during difficult times”, said Mr. Linh Ha, CEO of Nam Ha Pharmaceutical Joint Stock Company. “We appreciate the contributions of our employees, and will lead the company towards bigger goals in the future to deserve our position as a leading pharmaceutical enterprise in Vietnam”.

In the future, Nam Ha Pharmaceutical aims to achieve a revenue of 4000 billion VND (approx 169,4 million USD) in 2024, become a leading pharmaceutical company in Vietnam and Asia, and head toward building an FDA-GMP standard manufacturing facility, in an effort to bring Vietnamese pharmaceutical brands to international level. At the same time, the company will focus on perfecting and improving product quality; invest in research and production of many high-tech pharmaceutical products to treat and support the best treatment for patients, for the sake of public health.